Benzinga | Nov 17, 2021 07:30AM EST

EXCLUSIVE: Pasithea Therapeutics' Wholly Owned Subsidiary Pasithea Clinics To Launch In-Home Intravenous Ketamine Therapy In New York City, Los Angeles, San Diego, And San Francisco To Expand Its International Footprint

Miami Beach, FL / November 17, 2021 -- Pasithea Therapeutics Corp. (Nasdaq:

KTTA) ("Pasithea" or the "Company"), a novel biotechnology company focused

on the research and discovery of new and effective treatments for psychiatric

and neurological disorders, today announced that its wholly owned subsidiary,

Pasithea Clinics, commenced clinical operations, offering in-home intravenous

("IV") ketamine therapy to patients suffering from treatment-resistant mental

health issues. Initially, the treatment will be offered in New York City, Los

Angeles, San Diego, and San Francisco and will expand nationwide in the coming

months.

"The need for more effective treatment options for patients with mental health

disorders has never been greater. Ketamine, when used at sub-anesthetic doses,

has been shown to be highly effective in treating some psychiatric disorders.

Still, we need to broaden access to this treatment to a larger patient population

in a safe and convenient way. Through our mobile clinics, patients benefit from

receiving the ketamine therapy in the privacy and comfort of their own homes.

With patient safety as our top priority, all ketamine treatments will be delivered

by board-certified medical professionals. This launch is an important stepping

stone in expanding our international footprint in this space," stated Dr. Tiago

Reis Marques, CEO of Pasithea Therapeutics.

Patients with mental health disorders often struggle to complete day-to-day

activities, and even small tasks can take extra effort. In disorders such as

depression and post-traumatic stress disorder, symptoms such as fatigue, social

isolation, lack of motivation, and high levels of anxiety are frequent. The effort to

go to a physical clinic can be overwhelming. By providing this treatment at the

patient's home, Pasithea aims to broaden access to this important therapy.

"We are pleased to commence our U.S. rollout in major cities in New York and

California, with plans to scale our business in other cities over the coming

months. Although ketamine is a very safe drug to administer, there are still some

risks. Patient safety is of paramount importance, and we are providing a network

of highly trained medical professionals to administer this treatment in the

comfort of the patient s home. Our medical team ensures that our patients

receive state of the art support throughout their treatment experience. We

believe we can become the best-in-class and largest provider of IV ketamine

treatments in the United States. We will use our at-home model to expand our

reach in the U.S. in a fast and accessible way," said Dr. Adam Nadelson,

Managing Director of Pasithea Clinics in the United States.

Ketamine is a U.S. Food and Drug Administration ("FDA") approved drug

introduced to the medical community as an anesthetic more than 50 years ago.

It has recently been repurposed for the treatment of psychiatric disorders using

significantly lower doses than in anesthesia and is now gaining ground as a

promising treatment for mental health disorders. In certain psychiatric

conditions, such as treatment-resistant depression ("TRD") and post-traumatic

stress disorder ("PTSD"), it has shown remarkable efficacy and a rapid and

sustained effect, and up to 70% of those who receive this treatment can

eventually show a clinical response. While the number of treatments suggested

is done on a case-by-case basis, a typical treatment plan consists of up to six

infusions in the interval of two to three weeks.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on

the research and discovery of new and effective treatments for psychiatric and

neurological disorders. With an experienced team of experts in the fields of

neuroscience and psychopharmacology, Pasithea is developing new molecular

entities for the treatment of psychiatric and neurological disorders. Pasithea is

also focused on addressing the needs of patients currently suffering with mental

illness by providing access to IV ketamine infusions both in clinics and in-home

settings.

Forward Looking Statements

This press release contains statements that constitute "forward-looking

statements." Forward-looking statements are subject to numerous conditions,

many of which are beyond the control of the Company. While the Company

believes these forward-looking statements are reasonable, undue reliance should

not be placed on any such forward-looking statements, which are based on

information available to the Company on the date of this release. These forward-

looking statements are based upon current estimates and assumptions and are

subject to various risks and uncertainties, including, without limitation, those set

forth in the Company's filings with the SEC. Thus, actual results could be

materially different. The Company undertakes no obligation to update these

statements whether as a result of new information, future events or otherwise,

after the date of this release, except as required by law.